It's more than a result.
It's a person.

We're Driven To Know.

genetics-icon
Genetics

Innovative solutions that empower researchers, from ALS to fragile X syndrome.

Learn more about our Genetics portfolio
oncology-icon
Oncology

Solving complex molecular challenges, from leukemia to solid tumors.

Learn more about our Oncology portfolio
cdx-icon
Custom & Companion Diagnostics

One partner from clinical concept to product commercialization.

Learn more about partnering with us.
Spotlight

FDA Grants Premarket Clearance of Asuragen’s AmplideX® Fragile X Dx and Carrier Screen Kit

Our AmplideX® Fragile X Dx and Carrier Screen Kit has been cleared by the United States Food and Drug Administration (FDA), making it the first and only test for the detection and quantification of expanded pathogenic repeat sequences to be cleared by the FDA.

Learn More
Spotlight

Asuragen Announces Launch of AmplideX® PCR/CE SMN1/2 Plus Kit

The AmplideX® PCR/CE SMN1/2 Plus Kit is a clinical research tool providing the most comprehensive analysis of SMN1 and SMN2 currently available from a commercial kit.

Learn more
Spotlight

Asuragen Expands Genetic Portfolio with Launch of AmplideX® PCR/CE HTT Kit

The AmplideX® PCR/CE HTT Kit is a simple, robust, and reliable test for the detection of CAG trinucleotide repeats within the HTT gene, aberrations which are associated with the development of Huntington’s Disease (HD).

Read more
Spotlight

Asuragen Develops Armored RNA Quant® SARS-CoV-2 Control

Asuragen, Inc has developed an Armored RNA Quant® SARS-CoV-2 Control for use in developing assays in response to the COVID-19 pandemic.

Learn more

The Latest from Asuragen

From Two Days to Four Hours: How the AmplideX® PCR/CE SMN1/2 Plus Kit Provides SMN1 and SMN2 Copy Number Information and More…
Back To
Top